B of A Securities Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $8
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $9 to $8.
B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $9 to $8.